Home | Articles
Published on:March 2023
Indian Journal of Pharmaceutical Education and Research, 2023; 57(2):617-624
Original Article | doi:10.5530/ijper.57.2.76

Impact of Regulatory Policy Changes on Generic Drug Prices in the United States


Authors and affiliation (s):

Rajender Singh1, 2, Swati Singh1, Anil Kumar2, GT Kulkarni3,*, Arti R Thakkar1,*

1Amity Institute of Pharmacy, Amity University Uttar Pradesh, Noida, Uttar Pradesh, INDIA.

2Mankind Research Centre, IMT Manesar, Gurgaon, Haryana, INDIA.

3Gokaraju Rangaraju College of Pharmacy, Hyderabad, Telangana, INDIA.

Abstract:

Introduction: Generic Drug User Fee Act (GDUFA) was introduced in 2012 to bring more and more generic drugs into the market in a short time through an effective review process. In the present study, the impact of the GDUFA on prices of the generic drugs has been evaluated. Materials and Methods: Various research reports related to drug costs and competition such as (i) reasons for high drug prices, (ii) FDA’s research on drug prices pre- and post- GDUFA, and (iii) the current status of generic drugs in the USA produced by different agencies including the Congressional Budget Office (CBO), FDA’s Center for Drug Evaluation and Research (CDER), and the Federal Trade Commission (FTC) to understand the challenges of high drug costs have been critically evaluated. Results and Discussion: The analysis of research reports generated over some time concludes that the fall in generic drug prices has been accelerated further in recent years, with increased competition. The data analysis also reflects that during the GDUFA period, the Agency has been able to proactively address the challenges posed by brand-product companies. However, some issues remain to be addressed. Conclusion: The scope of this evaluation was limited to focus on FDA-related aspects where generic competition can be enhanced by making the generic drug approval process more efficient, continue to facilitate industry on complex products regulation to bring generic equivalents of complex products where patents expired long-time back, help resolve shortages faster and help expedite resolution of site compliance matters more quickly to assist in resuming supplies.

Keywords: Congressional Budget Office (CBO), Federal Trade Commission (FTC), Generic Drug User Fee Act (GDUFA), USFDA, Drug Prices.

 




 

Impact Factor

IJPER - An Official Publication of Association of Pharmaceutical Teachers of India is pleased to announce continued growth in the Latest Release of Journal Citation Reports (source: Web of Science Data).

 

Impact Factor® as reported in the 2023 Journal Citation Reports® (Clarivate Analytics, 2023): 0.8

The Official Journal of Association of Pharmaceutical Teachers of India (APTI)
(Registered under Registration of Societies Act XXI of 1860 No. 122 of 1966-1967, Lucknow)

Indian Journal of Pharmaceutical Education and Research (IJPER) [ISSN-0019-5464] is the official journal of Association of Pharmaceutical Teachers of India (APTI) and is being published since 1967.

DOI HISTORY

IJPER uses reference linking service using Digital Object Identifiers (DOI) by Crossref. Articles from the year 2013 are being assigned DOIs for its permanent URLs